TABLE 2.
Baseline and week 12 geometric means and percentage change in the geometric mean from baseline by treatment group for outcomes measured in Bangladeshi adults participating in a folic acid and creatine randomized, controlled trial1
| Placebo | Cr | P(Cr vs. placebo)2 | FA | Cr+FA | P(Cr+FA vs. FA)2 | |
| Plasma Cr+Crn | n = 101 | n = 101 | n = 130 | n = 102 | ||
| Baseline mean (95% CI) | 78 (74, 83) | 74 (70, 79) | 0.21 | 77 (73, 82) | 77 (72, 82) | 0.91 |
| Week 12 mean (95% CI) | 76 (72, 80) | 123 (113, 133) | <0.0001 | 78 (74, 82) | 124 (115, 132) | <0.0001 |
| % change (95% CI) | −2.7 (−6.9, 1.7) | 65.5 (51.1, 81.2) | <0.0001 | 1.2 (−4.1, 6.7) | 60.9 (49.8, 72.8) | <0.0001 |
| Plasma GAA | n = 101 | n = 101 | n = 130 | n = 102 | ||
| Baseline mean (95% CI) | 1.9 (1.8, 2.1) | 1.9 (1.8, 2.0) | 0.38 | 1.8 (1.7, 1.9) | 1.9 (1.8, 2.0) | 0.28 |
| Week 12 mean (95% CI) | 2.0 (1.9, 2.1) | 1.7 (1.6, 1.8) | <0.0001 | 1.9 (1.8, 2.0) | 1.7 (1.6, 1.8) | 0.01 |
| % change (95% CI) | 3.7 (−0.8, 8.5) | −10.6 (−15.9, −4.9) | 0.0002 | 7.0 (2.0, 12.2) | −9.0 (−14.2, −3.4) | <0.0001 |
| Blood SAM | n = 76 | n = 89 | n = 139 | n = 94 | ||
| Baseline mean (95% CI) | 2.1 (2.0, 2.3) | 2.0 (1.9, 2.1) | 0.19 | 2.1 (2.0, 2.2) | 2.0 (1.9, 2.1) | 0.15 |
| Week 12 mean (95% CI) | 2.1 (2.0, 2.3) | 2.1 (1.9, 2.2) | 0.66 | 2.1 (2.0, 2.2) | 2.0 (1.9, 2.1) | 0.11 |
| % change (95% CI) | −0.8 (−5.9, 4.5) | 3.1 (−2.8, 9.5) | 0.33 | 1.1 (−3.3, 5.6) | 0.6 (−4.5, 6.0) | 0.90 |
| Blood SAH | n = 68 | n = 86 | n = 127 | n = 84 | ||
| Baseline mean (95% CI) | 0.21 (0.19, 0.24) | 0.22 (0.19, 0.25) | 0.84 | 0.21 (0.19, 0.23) | 0.22 (0.19, 0.25) | 0.43 |
| Week 12 mean (95% CI) | 0.21 (0.18, 0.24) | 0.22 (0.20, 0.25) | 0.42 | 0.22 (0.20, 0.24) | 0.24 (0.22, 0.27) | 0.17 |
| % change (95% CI) | −2.1 (−13.6, 10.9) | 3.5 (−10.6, 19.7) | 0.57 | 4.7 (−5.1, 15.5) | 8.9 (-5.0, 24.9) | 0.64 |
| Plasma tHcys | n = 101 | n = 101 | n = 153 | n = 103 | ||
| Baseline mean (95% CI) | 12.2 (11.2, 13.4) | 11.4 (10.5, 12.3) | 0.24 | 11.9 (11.1, 12.9) | 11.8 (10.9, 12.7) | 0.82 |
| Week 12 mean (95% CI) | 12.1 (11.1, 13.1) | 10.9 (10.1, 11.7) | 0.07 | 9.1 (8.7, 9.6) | 9.3 (8.8, 9.8) | 0.60 |
| % change (95% CI) | −1.3 (−5.4, 3.1) | −4.3 (−9.0, 0.7) | 0.35 | −23.4 (−27.1, −19.5) | −21.0 (−25.2, −16.4) | 0.41 |
| Plasma tCys | n = 101 | n = 101 | n = 153 | n = 103 | ||
| Baseline mean (95% CI) | 218 (210, 226) | 215 (207, 224) | 0.63 | 216 (210, 223) | 213 (204, 222) | 0.56 |
| Week 12 mean (95% CI) | 222 (215, 230) | 227 (219, 236) | 0.40 | 223 (217, 229) | 224 (216, 232) | 0.87 |
| % change (95% CI) | 2.1 (−0.4, 4.7) | 5.7 (2.6, 9.0) | 0.08 | 3.2 (1.1, 5.4) | 5.2 (2.5, 8.0) | 0.26 |
All geometric mean units are μmol/L. Percentage change defined as (geometric mean ratio – 1) × 100. Cr, 3 g/d creatine group; Cr+Crn, creatine plus creatinine; Cr+FA, 3 g/d creatine plus 400 μg/d folic acid group; FA, 400 μg/d folic acid group; GAA, guanidinoacetate; SAH, s-adenosylhomocysteine; SAM, s-adenosylmethionine; tCys, total cysteine; tHcys, total homocysteine.
From 2-sample t tests comparing ln-transformed outcomes or within-person change in ln-transformed outcomes between the placebo and Cr groups, or between the FA and Cr+FA groups.